Publications by authors named "F B Keane"
Article Synopsis
Article Synopsis
- Adjuvant mFOLFIRINOX (mFFX) is a standard treatment for patients with resected pancreatic ductal adenocarcinoma (PDAC), but there is limited information on its effectiveness outside of clinical trials.
- A study of 147 patients showed a median recurrence-free survival (RFS) of 26 months, with some patients over 70 years experiencing a median overall survival (OS) of 51 months.
- Starting mFFX treatment within 8 weeks of surgery was linked to better survival outcomes, while certain genetic factors like KRAS mutations suggested poorer RFS and OS.
Article Synopsis
- The study investigates the role of microsatellite instability (MSI-H) in pancreatic cancer (PC) associated with Lynch syndrome (LS), focusing on both germline and somatic variants that affect mismatch repair genes.
- It involves a retrospective analysis of 55 PC patients at Memorial Sloan Kettering Cancer Center, revealing that a significant portion of those with LS and somatic MMR variants exhibit MSI-H status, which could impact treatment responses to immune therapy.
- Results showed that 59% of LS cohort patients had MSI-H, whereas 43% in the somatic MMR cohort had the same status, suggesting distinct genetic characteristics and age differences at diagnosis between the two groups.
Mutation in nucleophosmin (NPM1) causes relocalization of this normally nucleolar protein to the cytoplasm (NPM1c+). Despite NPM1 mutation being the most common driver mutation in cytogenetically normal adult acute myeloid leukemia (AML), the mechanisms of NPM1c+-induced leukemogenesis remain unclear. Caspase-2 is a proapoptotic protein activated by NPM1 in the nucleolus.
View Article and Find Full Text PDFIntroduction: Immune checkpoint inhibitor (ICI) combinations extend overall survival (OS) while anti-PD-1/L1 monotherapy is non-inferior to sorafenib in treatment-naïve, patients with advanced hepatocellular carcinoma (HCC). Clinicogenomic features are posited to influence patient outcomes.
Methods: The primary objective of this retrospective study was to define the clinical, pathologic, and genomic factors associated with outcomes to ICI therapy in patients with HCC.